...A. This is a business that grows -- we expect to grow 3%, and it's really driven by our kind of our broad portfolio across brands, across generics in key markets like Italy and France, as well as new product introductions like generic (inaudible). B. I mean the U.S. market, currently for us, is kind of less than 20% of our revenue. C. So China, actually, about 95% of our business in China has already gone through VBP. D. And we expect to continue to return capital to shareholders, but also invest in the business to be able to drive future growth. E. In the first quarter, we returned $393 million via both share buyback and dividends. F. And it's been documented that with P2Y12 that are not given at the right time and not given to the right patient necessarily, that 20% is conservative. G. We have over 6,000 patients randomized at this point....
